Russ Conroy

Articles

Transposon-Based BAFF CAR T Cells Show Early Efficacy, Safety in R/R Non-Hodgkin Lymphoma

November 14th 2024

Transposon-engineered BAFF ligand–based CAR T cells induced responses with a tolerable safety profile among 3 patients with relapsed/refractory B-cell NHL.

IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors

November 11th 2024

The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,

Temozolomide/Pembrolizumab Plus TTFields Leads to Tumor Control in Newly Diagnosed Glioblastoma

November 11th 2024

Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.

E-602 Plus Cemiplimab Elicits Preliminary Antitumor Activity, Is Safe in PD-(L)1–Resistant Solid Tumors

November 11th 2024

E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.

Adolescents/Young Adults With Cancer Experience Increased Financial Toxicity, Unmet Social Needs

October 23rd 2024

Routine screening revealed high financial toxicity and unmet social needs among adolescent and young adults with cancer.

MR-Linac Radiotherapy Limits Target Volume, Brain Tissue Exposure in High-Grade Glioma

October 11th 2024

MR-Linac adaptive radiotherapy plus temozolomide reduces CTV margins in high-grade glioma, according to results from the phase 2 UNITED trial.

Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer

October 8th 2024

The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.

Atezolizumab Plus Chemoradiation Provides No Survival Benefit in LS-SCLC

October 6th 2024

Atezolizumab administered concurrently with chemoradiation failed to improve OS and PFS outcomes compared with standard chemoradiation alone in LS-SCLC.

HDP-101 Shows Early Efficacy and Manageable Safety Profile in Relapsed/Refractory Multiple Myeloma

October 2nd 2024

The BCMA-targeting ADC HDP-101 demonstrated early efficacy and manageable toxicity in relapsed/refractory multiple myeloma.

Talquetamab-Based Triplet Elicits Deep Responses in R/R Myeloma

September 27th 2024

Talquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.

Talquetamab Plus Teclistamab Demonstrates Durable Responses in Triple Class–Exposed R/R Myeloma

September 27th 2024

Combining talquetamab with teclistamab demonstrated responses even among those with extramedullary disease in the RedirecTT-1 trial.

Belantamab Mafodotin Plus VRd Demonstrates Efficacy in Newly Diagnosed, Transplant-Eligible Myeloma

September 26th 2024

Belantamab mafodotin-based combination appears to improve responses over time in those with transplant-eligible newly diagnosed multiple myeloma

Breastfeeding During Endocrine Therapy Interruption Is Feasible, Does Not Adversely Affect Recurrence Rates in HR+ Breast Cancer

September 24th 2024

Patients with HR-positive breast cancer who conceived during a break from endocrine therapy found breastfeeding feasible and safe.

Nonoperative Management Maintains DFRS, Promotes Organ Preservation in pMMR Rectal Cancer

September 16th 2024

In the NO-CUT trial, 97% of patients with pMMR locally advanced rectal cancer sustained distant relapse-free survival with nonoperative management.

Adjuvant Ribociclib Sustains DFS, DDFS Benefit in HR+/HER2– Breast Cancer

September 16th 2024

Adding ribociclib to a NSAI in the adjuvant setting prolonged invasive and distant disease-free survival in HR-positive, HER2-negative early breast cancer.

Consolidation Durvalumab Shows Consistent Survival Benefit in LS-SCLC Regardless of Prior PCI and CRT Components

September 13th 2024

Consistent survival benefit was seen with consolidation durvalumab across subgroups in the ADRIATIC trial affirms its use as a standard of care in LS-SCLC.

Adjuvant Durvalumab Fails to Boost DFS in Resected NSCLC, Irrespective of PD-L1 Status

September 13th 2024

Adjuvant durvalumab did not provide a disease-free survival advantage over placebo in patients with NSCLC across different PD-L1 subgroups.

Amivantamab Plus Lazertinib Delays Symptomatic Progression in EGFR+ Advanced NSCLC

September 11th 2024

Patients with EGFR-mutated NSCLC demonstrated reduced symptom progression when treated with amivantamab plus lazertinib vs osimertinib.

Zongertinib Demonstrates Clinically Meaningful Efficacy in HER2-Mutated NSCLC

September 9th 2024

Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated non–small cell lung cancer.

BAY 2927088 Displays Durable Responses in HER2-Mutated NSCLC

September 9th 2024

BAY 2927088 demonstrated durable response rates for patients with pretreated HER2-mutant non–small cell lung cancer.